Technion researchers halt aggressive breast cancer growth with drug-free nanoparticles

Researchers at the Technion-Israel Institute of Technology have developed a nanoparticle treatment that halts the growth of aggressive triple-negative breast cancer tumors without using any chemotherapy drug -- a "medicine without drugs" approach the university says could open a chemical-free path for one of the hardest cancers to treat.

Triple-negative breast cancer lacks the three receptors most breast-cancer drugs target, making it unusually aggressive and resistant to standard therapy. Rather than attacking the cancer cells directly, the Technion team's nanoparticles -- engineered structures the researchers call MPsomes -- target the environment surrounding the tumor instead. The particles act as a biological decoy, competing with harmful immune cells for binding sites in the tumor microenvironment and delivering their own biological signal to the tissue and immune cells around the tumor.

In cell-culture and preclinical mouse-model testing, the particles accumulated at high concentrations around the tumor and inhibited its growth with effectiveness the researchers describe as comparable to existing drug treatments -- without a single drug molecule being released. The work, led by Ofri Vizenblit and Rawan Mhajne under the supervision of Assistant Professor Assaf Zinger at the Technion's Wolfson Faculty of Chemical Engineering, was published in the peer-reviewed journal ACS Nano.

The research remains at the preclinical stage: it has been tested in cell cultures and in mice, not yet in human clinical trials, and the university's own announcement frames the approach as a promising direction rather than an approved treatment. If it eventually reaches the clinic, a chemical-free method of halting an aggressive cancer's growth would sidestep some of the toxicity that limits how much conventional chemotherapy a patient can tolerate.

The project is one entry in a wider pattern of Israeli life-science research aimed at re-engineering how the immune system itself is recruited against disease, rather than only searching for new drug compounds.